CCXI

Jan 12, 2021 (The Expresswire) -- Global Diabetic Nephropathy Market Research Report focuses on market size, status and forecast 2020-2025, along with this...

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Dec. 20)

As in ANCA vasculitis, avacopan demonstrated statistically significant improvement in renal function as measured by eGFR compared to placebo over 26 weeks of blinded treatment The change from baseline to Week 26 in C3

Shares of ChemoCentryx (NASDAQ:CCXI) fell 8.59% in after-market trading after the company reported Q3 results.Quarterly Results Earnings per share were down 59.09% year over year to ($0.35), which missed the estimate of ($0.31).Revenue of $5,085,000 declined by 51.94% from the same period last year, which missed the estimate of $10,700,000.Guidance ChemoCentryx hasn't issued any earnings guidance for the time being.ChemoCentryx hasn't issued any revenue guidance for the time being.How To Listen To The Conference Call Date: Nov 09, 2020View more earnings on CCXITime: 05:00 PMET Webcast URL: https://edge.media-server.com/mmc/p/ehp3weoiPrice Action Company's 52-week high was at $65.43Company's 52-week low was at $7.88Price action over last quarter: Up 8.05%Company Description ChemoCentryx Inc is a biopharmaceutical company involved in discovery, development, and commercialization of orally administered drugs to treat rare diseases, inflammatory disorders, autoimmune diseases, and cancer. The company's approach is to target the chemoattractant system, defined as a network of molecules (for example, chemokine ligands, their associated receptors, and chemoattractant receptors) known to cause inflammation. The targeted therapeutic areas are an antineutrophil cytoplasmic antibody, atypical hemolytic uremic syndrome, immunoglobulin A-mediated nephropathy (rare diseases category), pancreatic cancer, chronic kidney disease, psoriasis, rheumatoid arthritis, asthma, Crohn's disease, inflammatory bowel disease, and others.See more from Benzinga * Click here for options trades from Benzinga * Earnings Outlook For ChemoCentryx * Benzinga's Top Upgrades, Downgrades For October 29, 2020(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

The possibility of a divided government is transpiring and bringing relief to health related stocks

-- Study Showed Treatment with Avacopan Achieved Statistical Superiority in Sustaining Remission at 52 Weeks and Greater Improvement in Renal Function Compared to the

Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 28)

JP Morgan analyst Anupam Rama downgrades ChemoCentryx (NASDAQ:CCXI) from Overweight to Neutral and lowers the price target from $63 to $60.